Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany, provides an overview of the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. They are celebrating the 20th anniversary of the study group with this meeting. Prof. Stilgenbauer further explains that there is a general tradition of collaboration in hematology research areas in Germany to run large trials, set new standards of care, and develop new drugs. The German CLL Study Group has been at the forefront of this development and we are living in very exciting times with a range of novel agents. The question is, who are the patients that benefit most from these specific agents. Prof. Stilgenbauer states that there is a need to run good biology programs and clinical trials along with combining forces in Germany and internationally to tackle this problem of finally finding a cure for chronic lymphocytic leukemia (CLL). Recorded at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany.